VHL anticorps (Internal Region)
-
- Antigène Voir toutes VHL Anticorps
- VHL (Von Hippel-Lindau Tumor Suppressor, E3 Ubiquitin Protein Ligase (VHL))
-
Épitope
- Internal Region
-
Reactivité
- Humain, Souris, Rat, Chien
-
Hôte
- Chèvre
-
Clonalité
- Polyclonal
-
Conjugué
- Cet anticorp VHL est non-conjugé
-
Application
- Western Blotting (WB), Enzyme Immunoassay (EIA)
- Specificité
- This antibody is expected to recognize both reported isoforms of VHL (NP_000542.1 and NP_937799.1).
- Réactivité croisée (Details)
-
Species reactivity (expected):Canine.
Species reactivity (tested):Human, Mouse, Rat, - Purification
- Ammonium Sulphate Precipitation followed by antigen Affinity Chromatography using the immunizing peptide
- Immunogène
- Peptide with sequence C-RSLVKPENYRRLD, from the internal region of the protein sequence
- Top Product
- Discover our top product VHL Anticorps primaire
-
-
- Indications d'application
-
ELISA: 1/128000. Western Blot: 0.01 - 0.03 μg/mL.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user. - Restrictions
- For Research Use only
-
- Concentration
- 0.5 mg/mL
- Buffer
- Tris saline, pH ~7.3, 0.02 % Sodium Azide, 0.5 % BSA
- Agent conservateur
- Sodium azide
- Précaution d'utilisation
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Conseil sur la manipulation
- Avoid repeated freezing and thawing.
- Stock
- 4 °C/-20 °C
- Stockage commentaire
- Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
-
- Antigène
- VHL (Von Hippel-Lindau Tumor Suppressor, E3 Ubiquitin Protein Ligase (VHL))
- Autre désignation
- VHL (VHL Produits)
- Synonymes
- anticorps HRCA1, anticorps RCA1, anticorps VHL1, anticorps pVHL, anticorps BcDNA:RH61560, anticorps CG13221, anticorps DVhl, anticorps Dmel\\CG13221, anticorps Dvhl, anticorps VHL, anticorps d-VHL, anticorps d-vhl, anticorps dVHL, anticorps dmVHL, anticorps vhl, anticorps rca1, anticorps vhl1, anticorps hrca1, anticorps zgc:158722, anticorps Vhlh, anticorps von Hippel-Lindau tumor suppressor, anticorps von Hippel-Lindau, anticorps von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase, anticorps von Hippel-Lindau disease tumor suppressor, anticorps VHL, anticorps Vhl, anticorps vhl, anticorps CpipJ_CPIJ009992
- Sujet
- Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed.Synonyms: Protein G7, Von Hippel-Lindau disease tumor suppressor
- Poids moléculaire
- 19.7 kDa (NP_937799.1)
- ID gène
- 7428, 9606
- UniProt
- P40337
- Pathways
- Tube Formation, Signaling Events mediated by VEGFR1 and VEGFR2, Ubiquitin Proteasome Pathway
-